WebJan 9, 2024 · Editas, which has faced clinical delays and executive turnover, said Monday it will no longer develop gene editing treatments for two eye diseases, as well as halt investment in natural killer cell therapies for cancer. The company aims to find partners that can advance the programs instead. Web18 hours ago · For their last quarter, Editas Medicine (EDIT) reported earnings of -$0.88 per share, missing the Zacks Consensus Estimate of -$0.84 per share. This reflects a negative …
Did you know?
WebJul 27, 2024 · CAMBRIDGE, Mass., July 27, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the dosing and confirmed successful neutrophil and... WebApr 12, 2024 · Editas Medicine - EDIT News Today $7.25 +0.22 (+3.13%) (As of 03/31/2024 12:00 AM ET) Compare Today's Range $7.05 $7.38 50-Day Range $7.03 $11.53 52-Week …
WebJan 11, 2024 · CAMBRIDGE, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food … WebJan 9, 2024 · CAMBRIDGE, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced a strategic …
Web1 day ago · Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. Web1 day ago · Editas Medicine (EDIT) shares soared 20.3% in the last trading session to close at $7.65. The move was backed by solid volume with far more shares changing hands …
Web2 days ago · Emma Reeve joined the Editas Medicine Board of Directors in September 2024. Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 years of global financial experience across ...
WebAug 3, 2024 · The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial … hunter carefree humidifier plus filtersWebApr 28, 2024 · Jim Mullen, Editas’ Chairman, President and CEO, who will become Executive Chairman on June 1. Mullen: Data this year would be actually our EDIT-101 in LCA, and we’ve guided to that. We’ll ... hunter car lifts for saleWebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board … hunter carefree humidifiersWebAug 11, 2024 · The stock price of Editas Medicine (NASDAQ: EDIT), a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one... marty\u0027s resumeWeb2 days ago · Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today ... hunter cardiologyWebJan 11, 2024 · CAMBRIDGE, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared... hunter carnahan shoub byard and harshmanWebNov 30, 2024 · As a result of the IND approval, Editas will receive a $25 million milestone payment from Allergan—which agreed in August to develop and commercialize EDIT-101 under an up-to-$40 million... marty\u0027s restaurant waterford wi